Browse > Article
http://dx.doi.org/10.4062/biomolther.2007.15.3.156

The Study on Association of Calcium Channel SNPs with Adverse Drug Reaction of Calcium Channel Blocker in Korean  

Chung, Myeon-Woo (National Institute of Toxicological Research, Korea Food and Drug Administration)
Bang, Sy-Rie (National Institute of Toxicological Research, Korea Food and Drug Administration)
Jin, Sun-Kyung (National Institute of Toxicological Research, Korea Food and Drug Administration)
Woo, Sun-Wook (National Institute of Toxicological Research, Korea Food and Drug Administration)
Lee, Yoon-Jung (National Institute of Toxicological Research, Korea Food and Drug Administration)
Kim, Young-Sik (College of Medicine, University of Ulsan)
Lee, Jong-Keuk (College of Medicine, University of Ulsan)
Lee, Sung-Ho (Department of Thoracic & Cardiovascular Surgery, Anam Hospital, Korea University)
Roh, Jae-Sook (National Institute of Toxicological Research, Korea Food and Drug Administration)
Chung, Hye-Joo (National Institute of Toxicological Research, Korea Food and Drug Administration)
Publication Information
Biomolecules & Therapeutics / v.15, no.3, 2007 , pp. 156-161 More about this Journal
Abstract
Rapid advances in pharmacogenomic research have provided important information to improve drug selection, to maximize drug efficacy, and to minimize drug adverse reaction. The SNPs that are the most abundant type of genetic variants have been proven as valid biomarkers to give information on the prediction of pharmacokinetic/pharmacodynamic properties of drugs based on genotype. In order to elucidate a correlation between SNPs of calcium channel encoding gene and adverse reactions of calcium channel blockers, we investigated SNPs in CACNA1C gene known as a binding site of calcium channel blocker. 96 patients with hypertension who had taken or are taking an antihypertensive drug, 1,4-dihydropyridine (DHP) were included for analysis. These patients were composed of 47 patients with adverse drug reactions (ADR) such as edema from calcium channel blockers and 49 patients without ADR as a control group. The exons encoding the drug binding sites were amplified by PCR using specific primers, and SNPs were analyzed by direct sequencing. We found that there was no SNP in the exons encoding DHP binding site, but four novel SNPs in the exon-intron junction region. However, four novel SNPs were not associated with the ADR of calcium channel blockers. In conclusion, this study showed that ADR from calcium channel blockers may not be caused by SNPs of the binding sites of calcium channel blockers in CACNA1C gene.
Keywords
Calcium channel blocker; Adverse Drug Reaction; SNP; CACNA1C gene; Korean;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Furukawa, T., Nukada, T., Suzuki, K., Fujita, Y., Mori, Y., Nishimura, M. and Yamanaka, M. (1997). Voltage and pH dependent block of cloned N-type Ca2+ channels by amlodipine. Br. J. Pharmacol 121, 1136-1140   DOI   ScienceOn
2 Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S. and Schulman, K.A. Implications of pharmacogenomics for drug development and clinical practice. Arch. Intern. Med. (2005). 165, 2331-2336   DOI   ScienceOn
3 Guo, Y., Shafer, S., Weller, P., Usuka, J. and Peltz, G. (2005). Pharmacogenomics and drug development. Pharmacogenomics 6, 857-864   DOI   ScienceOn
4 Aellig, W. H. (1998). Adverse reactions to antihypertensive therapy. Cardiovasc Drugs Ther 18(Suppl.): 55-58
5 Barone, F. C., Feuerstein, G. Z. and Spera, R. P. (1997). Calcium channel blockers in cerebral ischaemia. Expert Opin Investig Drugs 6, 501-519   DOI   ScienceOn
6 Birnbaumer, L., Campbell, K. P., Catterall, W. A., Harpold, M. M., Hofmann, F., Horne, W. A., Mori, Y., Schwartz, A., Snutch, T. P. and Tanabe, T. (1994). The naming of voltagegated calcium channels. Neuron 13, 505-506   DOI   ScienceOn
7 Dalen, P., Dahl, M. L., Roh, H. K., Tybring, G., Eichelbaum, M., Wilkinson, G. R. and Bertilsson, L. (2003). Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. Br. J. Clin. Pharmacol. 55, 630-634   DOI   ScienceOn
8 Hering, S., Berjukow, S., Aczel, S. and Timin, E.N. (1998). $Ca^{2+}$ channel block and inactivation: common molecular determinants. Trends Pharmacol Sci 19, 439-443   DOI   ScienceOn
9 De Leeuw, P.W. and Birkenhager, W. H. (2002). The effects of calcium channel blockers on cardiovascular outcomes: a review of randomised controlled trials. Blood Press 11, 71-78   DOI
10 Ertel, E. A., Campbell, K. P., Harpold, M. M., Hofmann, F., Mori, Y., Perez-Reyes, E., Schwartz, A., Snutch, T. P., Tanabe, T. and Birnbaumer, L. (2000). Nomenclature of voltage-gated calcium channels. Neuron 25, 533-535   DOI   ScienceOn
11 Hockerman, G. H., Peterson, B. Z., Johnson, B. D. and Catterall, W. A. (1997). Molecular determinants of drug binding and action on L-type calcium channels. Annu. Rev. Pharmacol. Toxicol. 37, 361-396   DOI   ScienceOn
12 Hofmann, F., Biel, M. and Flockerzi, V. (1994). Molecular basis for $Ca^{2+}$ channel diversity. Annu. Rev. Neurosci. 17, 399-418   DOI   ScienceOn
13 Kim, Y. S., Park, H. S., Sunwoo, S., Byeon, J. J., Song, Y. M., Seo, H. G., Kim, C. H., Cheon, K. S., Yoo, S. M. and Lee, J. K. (2000). Short-term safety and tolerability of antihypertensive agents in Korean patients: an observational study. Pharmacoepidemiol. Drug Saf. 9, 603-609   DOI   ScienceOn
14 Lee, J. K., Kim, H. T., Cho, S. M., Kim, K. H., Jin, H. J., Ryu, G. M., Oh, B., Park, C., Kimm, K. and Jo, S. A. (2003). Characterization of 458 single nucleotide polymorphisms of disease candidate genes in the Korean population. J. Hum. Genet. 48, 213-2   DOI
15 Lesko, L. J. and Woodcock, J. (2004). Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. Drug. Discov. 3, 763-769   DOI   ScienceOn
16 Mango, R., Vecchione, L., Raso, B., Borgiani, P., Brunetti, E., Mehta, J. L., Lauro, R., Romeo, F. and Novelli, G. (2005). Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. Expert Opin. Pharmacother. 6, 2565-2576   DOI   ScienceOn
17 Licinio, J. and Wong, M. -L. (2002). Pharmacogenomics : the search for individualized therapies Weinheim, Wiley-VCH
18 Linder, M. W., Prough, R. A. and Valdes, R. (1997). Jr. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem. 43, 254-266
19 Little, S. (2005). The impact of FDA guidance on pharmacogenomic data submissions on drug development. IDrugs 8, 648-650
20 Marsh, S., and McLeod, H. L. (2006). Pharmacogenomics: from bedside to clinical practice. Hum. Mol. Genet. 15 Spec No 1, R89-93   DOI   ScienceOn
21 Mason, R. P., Marche, P. and Hintze, T. H. (2003). Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler. Thromb. Vasc. Biol. 23, 2155-2163   DOI   ScienceOn
22 Meyer, U. A. (2000). Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671   DOI   ScienceOn
23 Muntwyler, J. and Follath, F. (2001). Calcium channel blockers in treatment of hypertension. Prog. Cardiovasc. Dis. 44, 207-216   DOI   ScienceOn
24 Nakagawa, K. and Ishizaki, T. (2000). Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol. Ther. 86, 1-28   DOI   ScienceOn
25 Relling, M. V., Hancock, M. L., Rivera, G. K., Sandlund, J. T., Ribeiro, R. C., Krynetski, E. Y., Pui, C. H. and Evans, W. E. (1999). Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer. Inst. 91, 2001-2008   DOI
26 Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D.J., Waterman, M. R., Gotoh, O., Coon, M. J. and Estabrook, R. W. (1996). P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1-42   DOI
27 Koytchev, R., Alken, R. G., Vlahov, V., Kirkov, V., Kaneva, R., Thyroff-Friesinger, U. and Rehak, E. (1998). Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur. J. Clin. Pharmacol. 54, 469-474   DOI
28 Regulla, S., Schneider, T., Nastainczyk, W., Meyer, H. E. and Hofmann, F. (1991). Identification of the site of interaction of the dihydropyridine channel blockers nitrendipine and azidopine with the calcium-channel alpha 1 subunit. Embo. J. 10, 45-49
29 Schmitz, G., Aslanidis, C. and Lackner, K. J. (2001). Pharmacogenomics: implications for laboratory medicine. Clin. Chim. Acta. 308, 43-53   DOI   ScienceOn
30 Severino, G. and Del Zompo, M. (2004). Adverse drug reactions: role of pharmacogenomics. Pharmacol. Res. 49, 363-373   DOI   ScienceOn
31 Liu, L., Fan, Q. I., El-Zaru, M. R., Vanderpool, K., Hines, R. N. and Marsh, J. D. (2000). Regulation of DHP receptor expression by elements in the 5'-flanking sequence. Am. J. Physiol Heart. Circ. Physiol. 278, H1153-1162   DOI
32 Singer, D., Biel, M., Lotan, I., Flockerzi, V., Hofmann, F. and Dascal, N. (1991). The roles of the subunits in the function of the calcium channel. Science 253, 1553-1557   DOI
33 Pequignot, M. O., Desguerre, I., Dey, R., Tartari, M., Zeviani, M., Agostino, A., Benelli, C., Fouque, F., Prip-Buus, C. and Marchant, D. (2001). New splicing-site mutations in the SURF1 gene in Leigh syndrome patients. J. Biol. Chem. 276, 15326-15329   DOI   ScienceOn
34 Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. and Sadee, W. (2001). Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J.A.M.A. 286, 2270-2279   DOI   ScienceOn
35 Pirmohamed, M. and Park, B. K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305. (2001)   DOI   ScienceOn
36 Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P., Steward, J. Q., McMunn, C., Ihrie, P., Mehall, J. M., Edwards, T. L. and Dawson, E. P. (2004). Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5, 895-931   DOI   ScienceOn
37 Striessnig, J., Grabner, M., Mitterdorfer, J., Hering, S., Sinnegger, M. J. and Glossmann, H. (1998). Structural basis of drug binding to L $Ca^{2+}$ channels. Trends Pharmacol Sci 19, 108-115   DOI   ScienceOn
38 Suen, T. C. and Goss, P. E. (2001). Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene. Oncogene 20, 440-450   DOI
39 Torpet, L.A., Kragelund, C., Reibel, J. and Nauntofte, B. (2004). Oral Adverse Drug Reactions to Cardiovascular Drugs. Crit Rev Oral. Biol. Med. 15, 28-46   DOI
40 Uneyama, H., Takahara, A., Dohmoto, H., Yoshimoto, R., Inoue, K. and Akaike, N. (1997). Blockade of N-type Ca2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br. J. Pharmacol. 122, 37-42   DOI   ScienceOn